Randomised, Placebo-controlled, Double-blind, Parallel-group Phase II Study to Evaluate the Efficacy and Safety of Oral BI 3000202 in Patients With Moderate to Severe Systemic Lupus Erythematosus (SLE)
Latest Information Update: 24 Feb 2026
At a glance
- Drugs BI 3000202 (Primary)
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
Most Recent Events
- 18 Feb 2026 New trial record